1093 CLN-617 combines IL-2 and IL-12 in a single molecule to optimally balance safety and efficacy upon intratumoral injection

• Naveen K Mehta,
• Patrick A Baeuerle,
• Jennifer S Michaelson,
• Laura Liu,
• K Dane Wittrup,
• Kristan A Meetze,
• Irina M Shapiro,
• Kavya Rakhra

Affiliations

Naveen K Mehta

1Cullinan Oncology, Inc., Cambridge, MA, USA

Patrick A Baeuerle

Cullinan Oncology Inc, Cambridge, Massachusetts, USA

Jennifer S Michaelson

Cullinan Oncology Inc, Cambridge, Massachusetts, USA

Laura Liu

1Cullinan Oncology, Inc., Cambridge, MA, USA

K Dane Wittrup

2Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA

Kristan A Meetze

1Cullinan Oncology, Inc., Cambridge, MA, USA

Irina M Shapiro

1Cullinan Oncology, Inc., Cambridge, MA, USA

Kavya Rakhra

1Cullinan Oncology, Inc., Cambridge, MA, USA